Combination of | |
---|---|
Naltrexone | Opioid receptor antagonist |
Bupropion | Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist |
Clinical data | |
Trade names | Contrave, Mysimba |
AHFS/Drugs.com | Monograph |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
KEGG | |
(what is this?) (verify) |
Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity.[4][6] It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant.[4] It is taken by mouth.[4] Both medications have individually shown some evidence of effectiveness in weight loss, and the combination has been shown to have some synergistic effects on weight.[7]
In September 2014, a sustained release formulation of the drug was approved for marketing in the United States under the brand name Contrave.[8][9] The combination was subsequently approved in the European Union in the spring of 2015, where it is sold under the name Mysimba.[5][10] It was approved in Canada under the Contrave brand name in 2018.[11]
fda20140911
was invoked but never defined (see the help page).